Summary
Comparison of clinical data of 64 patients with centroblastic lymphoma, 55 patients with immunoblastic lymphoma and 31 patients with lymphoblastic lymphoma not only confirmed the original assumption of high-grade malignancy as proposed by the concept of the Kiel classification but also demonstrated distinct clinical differences, particularly between lymphoblastic lymphoma and the two other entities. Rapid lymph node enlargement as well as steep fall of survival curves within the first year after diagnosis were common characteristics. Bimodal age distribution, predominance of males and early generalization of disease were typical features of lymphoblastic lymphoma; elderly patients and patients with the unclassified subtypes of lymphoblastic lymphoma exhibited the worst prognosis. Whereas patients with centroblastic and immunoblastic lymphomas showed similar distribution of age, sex and initial stage of disease, patients with immunoblastic lymphoma presented more frequently with a reduced performance status and showed a poorer response to radio- and chemotherapy resulting in a worse prognosis discernible after the first year of follow-up. Generalization during course of the disease was significantly more frequent in immunoblastic than in centroblastic lymphoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bagley CM Jr, DeVita VT Jr, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76: 227–234
Bartels H, Burger A, Common H, Donhuijsen-Ant R, Graubner M, Grupp HJ, Huhn D, Leopold H, Nowicki L, Nürnberger R, Rühl U, Waldner R (Kieler Lymphomgruppe) (1979) Klinik und Prognose des centroblastisch-centrocytischen Lymphoms und des centroblastischen Lymphoms. In: Stacher A, Höcker P (Hrsg) Lymphknotentumoren, Pathophysiologie, Klinik und Therapie. Urban u. Schwarzenberg, München Wien Baltimore, S 211–217
Bergsagel DE, Gospodarowicz M, Bush R, Brown TC (1979) Non-Hodgkin's lymphomas: A search for prognostic factors. In: Canonico A, Estevez O, Chacon R, Barg S (eds) Advances in Medical Oncology, Research and Education; Proceedings of the 12th International Cancer Congress Buenos Aires 1978, vol VII: Crowther DG (ed) Leukemia and Non-Hodgkin Lymphoma. Pergamon Press, Oxford New York Toronto Sydney Paris Frankfurt, pp 89–98
Brittinger G, Bartels H, Bremer K, Dühmke E, Gunzer U, König E, Stein H (Kieler Lymphomgruppe) (1976) Klinik der malignen Non-Hodgkin-Lymphome entsprechend der Kiel-Klassifikation: Centrocytisches Lymphom, centroblastisch-centrocytisches Lymphom, lymphoblastisches Lymphom, immunoblastisches Lymphom. In: Löffler H (Hrsg) Maligne Lymphome und monoklonale Gammopathien. Hämatologie und Bluttransfusion, Vol 18. Lehmann, München, S 211–223
Brittinger G (for the Kiel Lymphoma Study Group) (1978) Outline of a prospective multicentric study on the clinical significance of the Kiel classification of non-Hodgkin's lymphomas. In: Mathé G, Seligmann M, Tubiana M (eds) Lymphoid neoplasias II: Clinical and therapeutic aspects. Springer, Berlin Heidelberg New York (Recent Results in Cancer Research, vol 65, pp 197–202)
Brittinger G, Schmalhorst U, Bartels H, Brücher H, Common H, Dühmke E, Fülle HH, Gunzer U, Huhn D, König E, Lennert K, Leopold H, Meusers P, Nowicki L, Pralle H, Stacher A, Theml H (Kiel Lymphoma Study Group) (1979) Clinical relevance of the Kiel classification of non-Hodgkin lymphomas: Preliminary results of a prospective multicentric study. In: Tagnon HJ, Staquet MJ (eds) Controversies in cancer: Design of trials and treatment. Masson, New York Paris, pp 175–187
Brittinger G, Schmalhorst U, Bartels H, Fülle HH, Gerhartz H, Gremmel G, Grisar T, Grupp HJ, Gunzer U, Huhn D, Koeppen K-M, Kubanek B, Leopold H, Löffler H, Löhr GW, Nowicki L, Rühl U, Schmidt M, Stacher A, Theml H, Lennert K (Kiel Lymphoma Study Group) (1981) Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classification. Blut 43: 155–166
Brittinger G, Schmalhorst U, Bartels H, Bremer K, Brunswicker F, Burger A, Common H, Dühmke E, Fülle HH, Heinz R, Huber H, König E, Koeppen K-M, Leopold H, Meusers P, Nowicki L, Nürnberger R, Oertel J, Pees HW, Pfoch M, Pralle H, Schmidt M (1979) Chemotherapy of non-Hodgkin's lymphomas — Indications and results. In: Canonico A, Estevez O, Chacon R, Barg S (eds) Advances in Medical Oncology, Research, and Education; Proceedings of the 12th International Cancer Congress Buenos Aires 1978, vol. VII: Leukemia and Non-Hodgkin Lymphoma. Pergamon Press, Oxford New York Toronto Sydney Paris Frankfurt, pp 229–241
Canellos GP, Lister TA, Skarin AT (1978) Chemotherapy of the non-Hodgkin's lymphomas. Cancer 42: 932–940
Cutler SJ, Ederer F (1958) Maximum utilization of the life table method in analyzing survival. J Chronic Dis 8: 699–712
Delbrück H, Weichert HC, Schmitt G, Firusian N, Wetter O (1978) Der Zusammenhang zwischen Prognose und Kieler Klassifikation der malignen Non-Hodgkin-Lymphome. Klin Wochenschr 56: 539–543
DeVita VT Jr, Fisher RI, Young RC (1977) Treatment of diffuse histiocytic lymphomas: New opportunities for the future. In: Tagnon HJ, Staquet MJ (eds) Recent advances in cancer treatment. Raven Press, New York, pp 39–54
Elias L (1979) Differences in age and sex distribution among patients with non-Hodgkin's lymphoma. Cancer 43: 2540–2546
Fisher RI, DeVita VT, Johnson BL, Simon R, Young RC (1977) Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63: 177–182
Gunzer U, Bartels H, Burger A, Common H, Dabag S, Fülle HH, Huhn D, Leopold H, Löffler H, Nowicki L, Vogt W, Waldner R (Kieler Lymphomgruppe) (1979) Klinik und Prognose des lymphoblastischen Lymphoms. In: Stacher A, Höcker P (Hrsg) Lymphknotentumoren, Pathophysiologie, Klinik und Therapie. Urban u. Schwarzenberg, München Wien Baltimore, S 229–233
Karnofsky DA, Burchenal JH (1948) The evaluation of chemotherapeutic agents against neoplastic disease. Cancer Res 8: 388–389
Krüger GRF, Grisar T, Lennert K, Schwarze E-W, Brittinger G (Kiel Lymphoma Study Group) (1981) Histopathological correlation of the Kiel with the original Rappaport classification of malignant non-Hodgkin lymphomas. Blut 43: 167–181
Lennert K (1978) Malignant lymphomas other than Hodgkin's disease. Handbuch der speziellen pathologischen Anatomie und Histologie, 1. Band, Teil 3 B. Springer, Berlin Heidelberg New York
Meugé C, Hoerni B, DeMascarel A, Durant M, Richaud P, Hoerni-Simon G, Chauvergne J, Lagarde C (1977) Non-Hodgkin malignant lymphomas. Clinico-pathologic correlations with the Kiel classification. Eur J Cancer 14: 587–592
Meusers P, Bremer K, Bartels H, Brunswicker F, Burger A, Common H, Heinz R, Leopold H, Löffler H, Nowicki L, Vogt W, Waldner R, (Kieler Lymphomgruppe) (1979) Klinik und Prognose des immunoblastischen Lymphoms. In: Stacher A, Höcker P (Hrsg) Lymphknotentumoren, Pathophysiologie, Klinik und Therapie. Urban u. Schwarzenberg, München Wien Baltimore, S 224–228
Meusers P, Bartels H, Brittinger G, Common H, Dühmke E, Fülle HH, Gunzer U, Heinz R, König E, Musshoff K, Pralle H, Schmalhorst U, Theml H, Krüger GRF, Lennert K (Kiel Lymphoma Study Group) (1979) Heterogeneity of diffuse “histiocytic” lymphoma according to the Kiel classification. N Engl J Med 301: 384
Musshoff K, Schmidt-Vollmer H (1975) Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification. Z Krebsforsch 83: 323–341
Portlock CS, Rosenberg SA (1977) Chemotherapy of the non-Hodgkin's lymphomas: The Stanford experience. Cancer Treat Rep 61: 1049–1055
Strauchen JA, Young RC, DeVita VT, Anderson T, Fantone JC, Berard CW (1978) Clinical relevance of the histopathological subclassification of diffuse “histiocytic” lymphoma. N Engl J Med 299: 1382–1387
Author information
Authors and Affiliations
Consortia
Additional information
Supported by the Deutsche Krebshilfe e. V., Bonn
Rights and permissions
About this article
Cite this article
Schmalhorst, U., Bartels, H., Boll, I. et al. Clinical and prognostic heterogeneity of non-hodgkin lymphomas of high-grade malignancy. Blut 43, 201–211 (1981). https://doi.org/10.1007/BF00363890
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00363890